Neyssa Marina, Kay W. Chang, Marcio Malogolowkin, Wendy B. London, A. Lindsay Frazier, Richard B. Womer, Frederick Rescorla, Deborah F. Billmire, Mary M. Davis, Elizabeth J. Perlman, Roger Giller, Stephen J. Lauer and Thomas A. Olson Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors Cancer 104
Version of Record online: 5 JUL 2005 | DOI: 10.1002/cncr.21218
High-dose cisplatin combined with etoposide and bleomycin (HDPEB) improves event-free survival in advanced pediatric germ-cell tumors, but has significant ototoxicity. The authors combined amifostine with HDPEB and evaluated the efficacy and toxicity of this regimen, specifically whether ototoxicity decreased. Amifostine did not protect against ototoxicity associated with HDPEB.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field